

215A
CASE 4-20682D



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV4P366965PUS

Express Mail Label Number

12/14/04

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ALESSI ET AL.

APPLICATION NO: 10/823,433

FILED: APRIL 12, 2004

FOR: FOR RAC-PK AS A THERAPEUTIC AGENT OR IN DIAGNOSTICS,
SCREENING METHOD FOR AGENTS AND PROCESS FOR
ACTIVATING RAC-PK

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references, marked with an asterisk, are of record in parent Application No. 09/068,702, filed May 13, 1998; Application No. 09/091,109, filed June 11, 1998; Application No. 09/542,646, filed April 3, 2000; Application No. 10/147,123, filed May 16, 2002 and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7831


Date: 12/14/04

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-20682D
APPLICATION NO.
10/823,433
APPLICANT
ALESSI ET AL.
FILING DATE
APRIL 12, 2004

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,266,565	11/30/93	Lacoste et al.	514	114	
*	AB	5,278,154	1/11/94	Lacoste et al.	514	114	
*	AC	5,385,915	1/31/95	Buxbaum et al.	514	313	
*	AD	5,422,125	6/6/95	Skyler et al.	424	646	
	AE	5,932,243	8/3/99	Fricker et al.	424	450	
	AF	5,047,396	9/10/91	Orban et al.	514	11	
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
*	AM	0 245,979	11/19/87	Europe			<input type="checkbox"/> <input type="checkbox"/>
*	AN	0 264 278	4/20/88	Europe			<input type="checkbox"/> <input type="checkbox"/>
*	AO	0 521,787	1/7/93	Europe			<input type="checkbox"/> <input type="checkbox"/>
*	AP	0 551 200	7/14/93	Europe			<input type="checkbox"/> <input type="checkbox"/>
	AQ	0 539 319	12/8/99	Europe			<input type="checkbox"/> <input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)


	AR	Alessi et al., EMBO J 15 no. 23, pp 6541-6551
*	AS	Altomare et al., Oogene, vol. 11, pp 1055-1060, "Cloning, chromosomal localization and expression analysis of the mouse Akt2 oogene" (1995)
*	AT	Andjelkovic et al., Proceedings of the Natl. Academy of Sciences of the USA, vol. 93, no. 12, pp 5699-5704, Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase(1996)

EXAMINER DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-20682D
APPLICATION NO.
10/823,433
APPLICANT
ALESSI ET AL.
FILING DATE
APRIL 12, 2004

Group

EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BA	Boudewijn et al., Nature, vol 376, pp 599-603 (1995)
*	BB	Burgering et al., Nature, vol. 376, pp 599-603, "Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction (1995)
*	BC	Carey et al., Diabetes, vol. 44, no. 6, pp 682-688, "Okadaic Acid, vanadate, and Phenylarsine Oxide Stimulate 2-Deoxyglucose Transport in Insulin-Resistant Human skeletal Muscle" (1995)
*	BD	Chambers et al., Molecular Pharmacology, vol. 41, no. 6, pp 1008-1015, "Regulation by Phorbol Ester and protein Kinase C Inhibitors, and by a Protein Phosphatase Inhibitor (Okadaic Acid) of P-Glycoprotein Phosphorylation and Relationship to Drug Accumulat (1992)
*	BE	Cheng et al., Proc. Nat. Acad. Sci. USA, vol. 89, pp 9267-9271 (1992)
*	BF	Coffer et al., Eur. J. Biochem, Vol 201, no. 2, pp 475-481 (1991)
*	BG	Cross et al., Nature 378, no. 21, 785-789, Inhibition of glycogen synthase kinase-3 by insuling mediated by protein kinase B (1995)
*	BH	De Wit et al., Eur. J. Biochem., vol. 142(2) pp. 255-260 1984)t
*	BI	Dulhanty et al., Biochem. and Biophys., Rs. Comm., vol. 206, no. 1, pp 207-214 (1995)
	BJ	Embi et al, Eur. J. Biochem 107, pp 519-527
	BK	Early et al., Cell, Vol. 19, 981-992 "An Immunoglobulin Heavy Chain Variable Region Gene is Generated from Three Segments of DNA: (1980)
*	BL	Engel et al., J. Biolo. Chem., vol. 270, no. 45, pp 27213-27221 (1995)
*	BM	Franke et al., Cell, 81 pp 727-736, "the protein Kinase Encoded by the Akt Proto-Ocogene is a Target of the PDGF-Activated Phosphatidylinositol 3-Kinase" (1995)
	BN	Frech et al., J. Bio Chem 272, no. 13, pp 8474-8481 (1997)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-20682D
APPLICATION NO.
10/823,433
APPLICANT
ALESSI ET AL.
FILING DATE
APRIL 12, 2004

Group



FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	CA	WO 92/03423	3/2/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CB	WO 92/09891	6/11/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CC	WO 95/13820	5/26/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
*	CD	WO 97/18303	5/22/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CE	WO 91/19008	12/12/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CF	WO 97/22360	6/26/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CG	WO 97/22716	6/27/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>
	CL						<input type="checkbox"/>	<input type="checkbox"/>
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>
	CR						<input type="checkbox"/>	<input type="checkbox"/>
	CS						<input type="checkbox"/>	<input type="checkbox"/>
	CT						<input type="checkbox"/>	<input type="checkbox"/>
	CU						<input type="checkbox"/>	<input type="checkbox"/>
	CV						<input type="checkbox"/>	<input type="checkbox"/>
	CW						<input type="checkbox"/>	<input type="checkbox"/>
	CX						<input type="checkbox"/>	<input type="checkbox"/>
	CY						<input type="checkbox"/>	<input type="checkbox"/>
	CZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION


(Use several sheets if necessary)

ATTY. DOCKET NO.
4-20682D
APPLICATION NO.
10/823,433
APPLICANT
ALESSI ET AL.
FILING DATE
APRIL 12, 2004

Group

EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)



*	DA	Haslam et al., Nature, vol. 363, pp 309-310 (1993)
*	DB	Huang et al., Proc. Natl. Acad. Sci, USA, vol. 91, pp 8960-8963 (1994)
	DC	Hughes et al., Biochem J. 288, pp 309-314 (1994)
	DD	James et al., Biochem J. 315:709
*	DE	Jeno et al., Proc. Natl. Acad. Sci., USA, vol. 85, pp 406-410, "Identification and characterization of a mitogen-activated S6 kinase" (1988)
*	DF	Jones et al., Cell Regulation, vol. 2, pp. 1001-1009, "Molecular cloning of a second form of rac protein kinase" (1991)
*	DG	Jones et al., Proceedings of the Natl. Academy of Sciences of USA., vol. 88, pp 4171-4175, "Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily" (1991)
*	DH	Kohn et al., EMBO Journal, vol. 14, no. 17, pp 4288-4295. "Insulin stimulates the kinase activity of RAC-PK, pleckstrin homology domain containing ser/thr kinase (1995)
*	DI	Konishi et al., Biochemical and Biophysical Research Communications, vol.. 216, pp 526-534 (1995)
*	DJ	Konishi et al., Biochemical and Biophysical Research Communications, vol. 205, no. 1, pp 817-825 (1994)
*	DK	Michalak et al., Gen. Physiol Biophys. vol 13, 57-62, "Interaction of Erythrocyte Spectrin with some Nonbilayer Phospholipids
*	DL	Millward et al., Proc. Natl. Acad. Sci. USA, vol. 92, pp 5022-5026, "Molecular cloning and characterization of a conserved nuclear serine (threonine) protein kinase" (1995)
*	DM	Moeritz et al., Biomedica Biochimica Acta, vol. 42 (7-8) pp 989-995 (1983)
*	DN	Otsuka Pharm. KK, Derwent Abstract 91-019158/03 (JP 2292-217-A) 5/8/89
*	DO	Persaud et al., Biochemical Journal, vol. 313, no. 1, pp 119-124, "The mitogen-activated protein kinase pathway in rat islets of Langerhans: studies on the regulation of insulin secretion" (1996)

EXAMINE DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**FORM PTO-1449
(REV. 7-85)**

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
4-20682D
APPLICATION NO.
10/823,433
APPLICANT
ALESSI ET AL.
FILING DATE
APRIL 12, 2004

Group

**EXAMINER
INITIAL**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance.